Perrigo Pivots To 'Self Care' For 'Massive Opportunity' Beyond OTC Drugs
This article was originally published in The Rose Sheet
Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.
You may also be interested in...
Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.
Perrigo "walked away a little bit" from "a model that worked beautifully," says CEO Murray Kessler at investor conference, "In essence, all we've done over the last year is to put back in place the model that worked so well."
CEO Murray Kessler says Perrigo's history shows "when it looks like we were winning, there was a certain level of bolt-on" acquisitions in addition to new products. The combination drove Perrigo in Q3 with reported worldwide consumer product net sales up 3.3% to $961m.